Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Cocrystal reports SVR12 rate of 67% for CC-31244 regimen

Chris Lieu
January 25, 2019 8:07 PM UTC

Cocrystal Pharma Inc. (NASDAQ:COCP) reported preliminary data from an open-label, U.S. Phase IIa trial showing that eight of 12 (67%) evaluable patients with treatment-naïve HCV genotype 1 infection who received 400 mg oral CC-31244 plus Epclusa sofosbuvir/velpatasvir for two weeks followed by Epclusa alone for four weeks achieved a sustained virologic response (SVR) 12 weeks after the end of treatment. CC-31244 is a pan-genotypic nonstructural protein 5B (NS5B) non-nucleoside inhibitor (NNI)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Cocrystal Pharma Inc.